| Attributes | Values |
|---|
| rdf:type
| |
| description
| - videnskabelig artikel (da)
- article científic (ca)
- articolo scientifico (it)
- artigo científico (pt)
- bilimsel makale (tr)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научни чланак (sr)
- article scientifique (fr)
- artículu científicu espublizáu en 2008 (ast)
- наукова стаття, опублікована в травні 2008 (uk)
- scientific article published on 05 May 2008 (en)
- مقالة علمية نشرت في 05 مايو 2008 (ar)
- artykuł naukowy opublikowany 05 maja 2008 (pl)
- գիտական հոդված հրատարակված 2008 թվականի մայիսի 5-ին (hy)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| author name string
| |
| author name string
| - Brad H Pollock
- Otis W Brawley
- Magda Mendez
- Andra H James
- Llewellyn J Cornelius
- Danielle Laraque
- Charles Inturrisi
- Lawrence Robinson
- Aaron P Scholnik
- Bettye L Green
- Carolyn J Montoya
- Linda R Edwards
- Melissa Schori
- Vanessa Northington Gamble
|
| rdfs:label
| - National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (en)
- National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (nl)
- National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (ast)
|
| skos:prefLabel
| - National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (en)
- National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (nl)
- National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (ast)
|
| name
| - National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (en)
- National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (nl)
- National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (ast)
|
| title
| |
| title
| - National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.7326/0003-4819-148-12-200806170-00220
|
| is about
of | |
| is cites work
of | - Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?
- Cardiovascular abnormalities in sickle cell disease
- Sickle-cell disease
- An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease
- The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up
- How I use hydroxyurea to treat young patients with sickle cell anemia
- Update on the use of hydroxyurea therapy in sickle cell disease
- Impact of hydroxyurea on clinical events in the BABY HUG trial
- Fetal hemoglobin in sickle cell anemia
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
- Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia
- RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model
- Ribonucleotides in DNA: Origins, repair and consequences
- Stwl modifies chromatin compaction and is required to maintain DNA integrity in the presence of perturbed DNA replication.
- Attenuated maximal muscle strength and peak power in children with sickle cell disease
- Hydroxyurea in sickle cell disease: drug review
- Pharmacotherapy in sickle cell disease--state of the art and future prospects
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)